Literature DB >> 10566575

Prevalence of potential proton-pump inhibitor drug interactions: a retrospective review of prescriptions in community pharmacies.

E Saltiel1, A Fask.   

Abstract

Drug interactions are a major cause of drug-related problems. This study assessed the comparative frequency of potential drug-drug interactions in patients receiving either omeprazole or lansoprazole. We reviewed prescription data from 144 community pharmacies in 25 states for the period of October 12, 1996, through October 20, 1997, from which the rates at which patients received either proton-pump inhibitor concurrently with > or =1 potentially interacting drugs were determined. A total of 7306 patients received only omeprazole, and 2486 received only lansoprazole. In this sample, 722 patients (9.9%) who received omeprazole also received a potentially interacting medication at the same time, compared with 8 patients (0.3%) who received lansoprazole (P<0.001). These data suggest that clinicians should be conscientious when selecting or dispensing drugs for patients taking omeprazole, given the relatively high prevalence of potential drug interactions in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566575     DOI: 10.1016/S0149-2918(99)80059-9

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  2 in total

1.  Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

Authors:  Gianluca Trifirò; Salvatore Corrao; Marianna Alacqua; Salvatore Moretti; Michele Tari; Achille P Caputi; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

2.  Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.

Authors:  Majid Vakily; Ronald D Lee; Jingtao Wu; Lhanoo Gunawardhana; Darcy Mulford
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.